DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects
Psychopharmacology · 2024
DOI: 10.1007/s00213-024-06629-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmacology, 2024. Verfasst von Maiko Kitaichi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Drug Research Division, Sumitomo Pharma Co., Ltd., Osaka, 554-0022, Japan. Hauptthemen laut MEDLINE: Antidepressive Agents, Antipsychotic Agents, Receptors, Serotonin, Anti-Anxiety Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Current treatment of major depressive disorder is facing challenges, including a low remission rate, late onset of efficacy, and worsening severity due to comorbid symptoms such as psychosis and cognitive dysfunction. Serotonin (5-HT) neurotransmission is involved in a wide variety of psychiatric diseases and its potential as a drug target continues to attract attention. OBJECTIVES: The present study elucidates the effects of a novel 5-HT modulator, DSP-6745, on depression and its comorbid symptoms. RESULTS: In vitro radioligand binding and functional assays showed that DSP-6745 is a potent inhibitor of 5-HT transporter and 5-HT2A, 5-HT2C, and 5-HT7 receptors. In vivo, DSP-6745 (6.4 and 19.1 mg/kg as free base, p.o.) increased the release of not only 5-HT, norepinephrine, and dopamine, but also glutamate in the medial prefrontal cortex. The results of in vivo mouse phenotypic screening by SmartCube® suggested that DSP-6745 has a behavioral signature combined with antidepressant-, anxiolytic-, and antipsychotic-like signals. A single oral dose of DSP-6745 (6.4 and 19.1 mg/kg) showed rapid antidepressant-like efficacy in the rat forced swim test, even at 24 h post-dosing, and anxiolytic activity in the rat social interaction test. Moreover, DSP-6745 (12.7 mg/kg, p.o.) led to an improvement in the apomorphine-induced prepulse inhibition deficit in rats. In the marmoset object retrieval with detour task, which is used to assess cognitive functions such as attention and behavioral inhibition, DSP-6745 (7.8 mg/kg, p.o.) enhanced cognition. CONCLUSIONS: These data suggest that DSP-6745 is a multimodal 5-HT receptor antagonist and a 5-HT transporter inhibitor and has the potential to be a rapid acting antidepressant with efficacies in mitigating the comorbid symptoms of depression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Research Division, Sumitomo Pharma Co., Ltd., Osaka, 554-0022, Japan.
- Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
- Drug Research Division, Sumitomo Pharma Co., Ltd., Osaka, 554-0022, Japan. taro.kato@sumitomo-pharma.co.jp.
Zitieren
APA
Kitaichi, M., Kato, T., Oki, H., Tatara, A., Kawada, T., Miyazaki, K., Ishikawa, C., Kaneda, K., & Shimizu, I. (2024). DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects. Psychopharmacology. https://doi.org/10.1007/s00213-024-06629-2
Vancouver
Kitaichi M, Kato T, Oki H, Tatara A, Kawada T, Miyazaki K, et al. DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects. Psychopharmacology. 2024. doi:10.1007/s00213-024-06629-2
BibTeX
@article{Kitaichi2024,
author = {Kitaichi, Maiko and Kato, Taro and Oki, Hitomi and Tatara, Ayaka and Kawada, Takuya and Miyazaki, Kenji and Ishikawa, Chihiro and Kaneda, Katsuyuki and Shimizu, Isao},
title = {DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects},
journal = {Psychopharmacology},
year = {2024},
doi = {10.1007/s00213-024-06629-2}
}
EUVIMED